News

VIPC Regional Innovation Fund Grant Awarded to Charlottesville BioHub to Strengthen the Entrepreneurial Ecosystem in the Charlottesville Region

Funding will further Charlottesville BioHub’s goals to advance entrepreneurship in the area’s biotechnology sector and support tech and other innovation-led sectors with resourcing and connection

Charlottesville, Virginia – Charlottesville BioHub, an industry-led 501c3 nonprofit organization dedicated to strengthening Charlottesville’s biotechnology industry sector, today announced that it has received a $200,000 grant from the Virginia Innovation Partnership Corporation’s (VIPC) Regional Innovation Fund (RIF), an administered state-funded program that provides competitive grants to leading Virginia-based organizations that support entrepreneurship. Charlottesville BioHub is at the center of a thriving entrepreneurial ecosystem in the Charlottesville region, with many partners across economic development, industry, and academia.

Charlottesville BioHub’s Project InnoVAte aims to broaden the region’s network capital and connect high-growth, scalable startups in biotech, tech, and other innovation-led sectors to relevant programming and resourcing within the ecosystem.

“We are pleased to provide a Regional Innovation Fund grant to Charlottesville BioHub to support its efforts to strengthen Central Virginia’s biotechnology industry through engagement, resourcing, and education,” said Conaway Haskins, Vice President for Entrepreneurial Ecosystems at the Virginia Innovation Partnership Corporation. “The organization aims to double the size of the industry in its geographic footprint by 2030 by creating value and reducing barriers for companies to thrive and grow within the region. Over the past five years, Charlottesville BioHub has emerged as a linchpin to growing the region’s biotech and life sciences sector and it is serving as a model for other regional biotech hub efforts across Virginia.”

Project InnoVAte includes three initiatives:
• InnoVAte: An expanded Entrepreneurship-in-Residence (EIR) program will support company commercialization and business operations through education and advising for early-stage ventures.
• ActiVAte: Curated high-quality programming for entrepreneurs, ecosystem partners, students, and community members.
• CultiVAte: Ecosystem leader engagement and ecosystem network development to roadmap the region’s future.

 

Read more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business